mutations in addition to CALR mutation at diagnosis. He was still alive without disease progression at the time of this study, that is 57 months after diagnosis. Patient 2, diagnosed as having RA, had low-risk characteristics according to both the IPSS and the IPSS-R. She remained transfusion dependent during the follow-up period of 27.4 months. We did not find any CALR mutation in 98 patients with CMML or RAEBT at diagnosis. The variation of the incidence of CALR mutations in WHO-defined MDS (0-8.3%) in different studies 1, 2 and in this study may be due to bias in patient selection, ethnic and/or geographic differences, but more studies are needed to clarify it.
Intriguingly, among the 107 CALR-wild patients who were sequentially studied, one (patient 3, Table 1 ) acquired CALR mutation 33.5 months after diagnosis when the disease progressed from RAEBT to AML by the FAB classification ( Figure 1) . A novel RUNX1 mutation was also acquired at the same time in this patient. The CALR of other 106 patients remained in germline during follow-ups. Because direct sequencing might not be sensitive enough to detect low level of CALR mutant, we therefore did TA cloning followed by direct sequencing 7 for the three CALR-wild samples obtained at diagnosis and subsequent follow-ups from patient 3. We could not find any CALR mutation in the 65, 43 and 54 clones analyzed using cloning technique in this patient ( Table 1 and Figure 1 ). Nevertheless, we could not exclude the possibility that minor population of cells with CALR mutant existed initially but escaped the detection of direct sequencing or TA cloning technique.
In this study, two different kinds of CALR mutations (L367TfsX46 and K374NfsX55, Table 1 ) were detected in three patients. Both of these frame-shift mutations are predicted to generate mutant proteins with a novel C-terminal, resulting in the loss of most of the C-terminal acidic domain and the Lys-Asp-Glu-Leu (KDEL) signal. The KDEL signal is responsible for retrieval of endoplasmic reticulum (ER) luminal proteins from the Golgi apparatus and maintaining these proteins in the ER. 8 Therefore, these alterations are thought to compromise retrieval or retention of these proteins in the ER.
To the best of our knowledge, this study recruited the largest cohort of MDS patients to clarify the clinical relevance of CALR mutations in MDS. We showed that CALR mutations were rarely detected in patients with MDS both at diagnosis and disease progression.
Overexpression of anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL and Mcl-1, etc.) has been shown to cause resistance to chemotherapy in many cancer types, including AML. [3] [4] [5] Although inhibitors of this family have been promising, inhibition of Bcl-xL has been associated with platelet death and subsequent thrombocytopenia. 5, 6 Fortunately, the recently developed ABT-199 is specific for Bcl-2, making it an attractive potential option for the treatment of AML. [7] [8] [9] This study was designed to identify genetic subgroups, which may respond to ABT-199 favorably and biomarkers predicting ABT-199 sensitivity in AML. First, we screened 11 AML cell lines (CMS, CTS, HL-60, MOLM-13, MV4-11, NB4, OCI-AML3, THP-1, U937, CMK and CMY, Supplementary Table S1 ) for Bcl-2 family proteins and mRNA expression ( Supplementary Figures S1A-C) . In general, gene expression did not appear to follow any subtype distribution. Most cell lines expressed all three proteins, albeit at variable levels. We then tested the sensitivity of these cell lines to single-agent ABT-199 ( Supplementary Table S1 ). The cell lines exhibited a wide range of sensitivities, with inhibitory concentration (IC) 50 s ranging from 97 nM (HL-60) to 15 mM (OCI-AML3). Protein and transcript levels for the individual anti-apoptotic Bcl-2 family genes did not correlate with ABT-199 IC 50 (data not shown).
To confirm that ABT-199 caused cell death and not merely growth inhibition, annexin V and propidium iodide dual staining was used to measure apoptosis in five AML cell lines. ABT-199 was able to induce apoptosis in a dose-dependent manner in four of the five cell lines tested. In contrast, apoptosis was induced by up to 8 mM ABT-199 in OCI-AML3 cell line (the most resistant cell line determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays) was minimal ( Figure 1a ). The relative magnitude of this induction was in agreement with the ABT-199 sensitivities shown in Supplementary Table S1 . Interestingly, we found that AML cell lines harboring MLL fusion genes were particularly sensitive to ABT-199 compared with those that did not (median ABT-199 IC 50 s were 260 and 6.2 mM, respectively, P ¼ 0.016, Figure 1b ). Further, the two acute promyelocytic leukemia (APL, French-American-British (FAB) classified M3) cell lines (HL-60 and NB4) tended to be more sensitive to ABT-199 compared with the other AML cell lines.
To confirm that ABT-199 is effective against primary AML patient samples, we tested the drug ex vivo in freshly isolated AML blast samples (n ¼ 16). Similar to the cell line results, ABT-199 was able to induce a dose-dependent increase in apoptosis in two AML patient samples (Figure 1c ). The ABT-199 sensitivities for the primary AML samples were comparable to the cell lines (Table 1 & Supplementary  Table S1 ). Interestingly, AML patient samples with an APL phenotype were significantly more sensitive to single-agent ABT-199 compared with non-APL AML patient samples (median ABT-199 IC 50 s were 3.4 and 19 mM, respectively, P ¼ 0.002, Figure 1d ).
Efforts were then undertaken to identify biomarkers predicting ABT-199 sensitivity in AML cells. As previously reported for multiple myeloma, 8 (Figure 1g ).
In conclusion, we provide evidence supporting the further clinical investigation of ABT-199 in AML. While the AML cell lines demonstrated a range of sensitivities to single-agent ABT-199 therapy, one group appears to be particularly sensitive. Cell lines harboring MLL fusion genes were more sensitive, suggesting that MLL fusion genes have a common role in Bcl-2 mediated anti-apoptotic effects. Unfortunately, we were unable to obtain any patient samples with these abnormalities to confirm this finding. Based on the cell line data, patients, such as those with infant AML, 10 whose blast cells have a MLL gene rearrangement, may benefit from treatment with ABT-199; however, confirmation in patient samples is warranted.
Importantly, we found that, primary AML samples with the APL phenotype are particularly sensitive to single-agent ABT-199, suggesting a possible role for this agent in APL patients who do not respond to all-trans retinoic acid and/or arsenic trioxide-based therapies. This finding, although thus far only in a limited number of samples, has potential importance as patients with APL meet the exclusion criteria for the current phase II clinical trial investigating ABT-199 in AML (NCT01994837, clinicaltrials.gov). Further, our data from both AML cell lines and primary patient samples suggest that the ratios of Bcl-2/Mcl-1 transcripts may represent a good biomarker predicting ABT-199 sensitivity in acute leukemia. Our results further support the clinical development of ABT-199 for treatment of AML. Persistent polyclonal B-cell lymphocytosis (PPBL) is a rare disorder, which mostly affects middle-aged women and is associated with smoking. 1 It is characterized by the persistent expansion of CD27 þ IgM þ IgD þ B cells, the presence of circulating binucleated lymphocytes and increased IgM serum levels. [1] [2] [3] Furthermore, PPBL is associated with HLA-DRB1*07 carriership and a supernumerary isochromosome þ i(3q) in a small proportion of lymphocytes. 3 Although the disorder is usually benign, 4 B10% of patients present with mild splenomegaly and a few patients subsequently develop a mature B-cell malignancy, such as diffuse large B-cell lymphoma (DLBCL) or splenic marginal zone lymphoma (MZL). 4 Despite an increasing number of described cases, the nature of the persistent lymphocytosis and its relation to mature B-cell malignancies remain poorly understood. Therefore, we subjected PPBL patients and healthy controls to immunoglobulin (Ig) repertoire and replication history analyses, and gene expression profiling (detailed Materials and Methods online). Five patients (4 women, 1 man) were included with a moderate lymphocytosis of CD27 þ IgM þ IgD þ B cells that was persistent for 41 year ( Supplementary Table 1, Supplementary Figure 1a) . These cells showed a normal Igk/Igl ratio, but abnormally low CD38 and CD21 expression levels ( Supplementary  Figure 1b) . IGH-CDR3 immunospectratyping revealed polyclonal IGH rearrangements with a normal length distribution and inframe selection (Supplementary Figure 1c) . This was confirmed by detailed sequence analyses of 375 in-frame IGH gene rearrangements from sorted CD27 þ IgM þ IgD þ cells. Similar to healthy controls, each clone yielded a unique sequence, and diverse IGHV, IGHD and IGHJ genes were used without signs for preferential pairing (Supplementary Figure 2) . The IGHV1-2*04 allele that is associated with splenic MZL was used in only four rearrangements from three patients. 5 Considering that 4/5 patients carried an IGHV1-2*04 allele in their germline DNA, it did not seem preferentially rearranged in PPBL cells. Finally, the IGH-CDR3 size distribution in IGH gene rearrangements of PPBL was similar to control natural effector and IgM-only memory B cells ( Supplementary Figure 2f) . Thus, PPBL cells showed a diverse Ig gene repertoire with normal IGH-CDR3 size selection and without obvious selection for IGHV gene use.
To study the nature of the lymphocytosis, we quantified the in vivo replication history with Ig kappa-deleting recombination excision circles. 6 The observed proliferation of B16 cell divisions was significantly higher (Po0.05) than the replication histories of natural effector and IgM-only B cells of controls (Figure 1a) . Despite the increased number of cell divisions, PPBL showed low levels of SHM, both in an Igk CDR1 hotspot region and in IGHV genes (Figures 1b and c) . These low SHM frequencies did not seem to result from impaired activity of activation induced cytidine deaminase or the error-prone Polymerase Z, because targeting of RGYW/WRCY and WA/TW DNA sequence motifs in IGHV genes was normal (Supplementary Table 2 ). 7 To study signs of antigenic selection, we determined the replacement/silent mutation ratios for framework (FR) and complementary determining regions (CDR), and compared these with the Accepted article preview online 19 February 2014; advance online publication, 14 March 2014
